key: cord-0780340-7g4gjbsl
authors: Aguilar-Shea, Antonio L.; Vera-García, Mar; Güerri-Fernández, Robert
title: Rapid antigen tests for the detection of SARS-CoV-2: A narrative review
date: 2021-05-28
journal: Aten Primaria
DOI: 10.1016/j.aprim.2021.102127
sha: 4df70ea1056938d679d67c06099efdde2339b926
doc_id: 780340
cord_uid: 7g4gjbsl

The rapid identification and isolation of COVID-19 patients has become the cornerstone for the control of the recent outbreak. Real-time quantitative polymerase chain reaction is routinely used to confirm COVID-19 diagnosis and is considered the gold standard due to high sensitivity and specificity. Nevertheless, it usually takes several days and a relatively higher cost. Antigen tests based have emerged to cope with such disadvantages, by offering rapid results, an easy-to-use procedure, and low costs. The objective of the narrative review was to provide up-to-date data about CE-marked rapid antigen tests (RATs) for COVID-19. Given their large number, the study only focused on representative and widely used in Spain (Standard Q, Nadal, Panbio, CerTest, and Wondfo). Clinical sensitivity of RATs has demonstrated to be high; however there is some variability among studies. By contrast, overall specificity is consistently elevated in all of them.

Coronaviruses are an important family of pathogenic agents that affect the human respiratory system, and were responsible for worldwide outbreaks such as the severe acute respiratory syndrome (SARS)-CoV in 2003, or the Middle East respiratory syndrome (MERS)-CoV in 2012. 1, 2 By December 2019, a cluster of atypical pneumonia cases were reported in Wuhan (China). The etiological agent was identified as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its related disease was named as coronavirus disease 2019 . 3 The disease shows diverse clinical manifestations, i.e. from no or mild symptoms to severe pneumonia with multi-organ failure, including acute respiratory distress syndrome, sepsis, and septic shock. 4 On 30 th January 2020 the World Health Organization (WHO) declared COVID-19 outbreak to be a public health emergency of international concern; 5 the sixth after H1N1 (2009), Polio (2014), Ebola in West Africa (2014), Zika (2016) and Ebola in the Democratic Republic of Congo (2019). 6 The first case of COVID-19 in Spain was confirmed on 31 st January 2020. 7 Since then, a total of 3,096,343 individuals have been tested positive, and 65,979 ones have passed away. 8 The rapid identification and isolation of positive patients has become the cornerstone for the control of the COVID-19 outbreak. 9 Real-time quantitative polymerase chain reaction (RT-qPCR), with nasopharyngeal swabs, throat swabs, or saliva samples, is routinely used to confirm the COVID-19 diagnosis. 10 It is considered the gold standard due to its high sensitivity and specificity. 11 Nevertheless, RT-qPCR testing usually takes several days and relatively higher costs to be completed. It requires the transportation of samples from the place of collection to the specialized laboratory, 4-6 hours of methodology, limited laboratory capacity (trained staff, special equipment, reagents, disposables, etc.), and high sample volumes. 11 Antigen tests based on lateral flow immunoassays have emerged to cope with such a disadvantage scenario, by offering rapid results (10-30 minutes), through an easy-to-use procedure, and low costs. By December 2020, the European Commission purchased over 20 million rapid antigen tests (RATs) J o u r n a l P r e -p r o o f for European members, and stated recommendations for their use and validation. 12 The objective of the present narrative review was to provide up-to-date data about RATs for COVID-19 with European conformity (CE marked). Given their large number, 13 the study only focused on representative and widely used in Spain, i.e. Standard Q (SD Biosensor Inc., Republic of Korea;

F. Hoffmann-La Roche Ltd, Switzerland), Nadal (Nal von minden GmbH, Germany), Panbio (Abbott Laboratories GmbH, Germany), CerTest (Certest Biotec, S.L., Spain), and Wondfo (Guangzhou Wondfo Biotech Co. Ltd, China).

A systematic review of available studies involving RATs was carried out in PubMed database.

Keywords included: "antigen test", "COVID-19", "SARS-CoV-2", "Standard Q", "Roche", "Nadal", "Panbio", "Abbott", "CerTest", and "Wondfo". The date of search was February 18 th 2021. Only studies providing information about sensitivity and specificity of RATs were analyzed. With the aim of including more studies (especially preprint papers, studies that have not been published on PubMed, or information from manufacturers), manual searches were carried out in Google by using the same keywords.

The Standard Q test was the second commercialized RAT in Spain. It detects the presence of identified. Thus, overall sensitivity, specificity, PPV, and NPV were 70.6%, 100.0%, 100.0%, and 87.4%, respectively.

Nadal antigen test is another RAT widely used in Spain. 26 The test directly checks for the presence of specific SARS-CoV-2 nucleocapsid proteins in 15 minutes. According to the manufacturer's information, the diagnostic sensitivity is 80.2% (95%CI: 73.9-85.3%) for a Ct value 20-37 or 97.6% (95%CI: 93.1-99.2%; Table 2 ) if Ct value 20-30, and the diagnostic specificity is more than 99.9% (95%CI: 97.7-100.0). 26 These data derive from a study with 348 samples, 46.3% being RT-qPCR positive, and 43.1% Nadal test-positive. No false positives with Nadal test were reported. Few studies have been published to evaluate the Nadal antigen test for the diagnosis of SARS-CoV-2 infection. All of them have compared the analytical sensitivity, and clinical sensitivity and specificity in diverse RATs (Table 3) . 18 

Panbio was the first commercialized RAT for COVID-19 in Spain. 29 The test detects the presence of a SARS-CoV-2 nucleocapsid protein in nasal or nasopharyngeal swab specimens within 15 minutes. 30 (Table 3) . 31 

CerTest test represents the first commercialized RAT that is manufactured by a Spanish Biotech company. 42 It is also based on the qualitative detection of SARS-CoV-2 membrane proteins from nasopharyngeal swab samples. The only available information related to its clinical sensitivity and specificity derives from the leaflet of the manufacturer. 43 

Wondfo test is another commercialized and widely used RAT in Spain. It qualitatively detects a SARS-CoV-2 nucleocapsid protein in nasopharyngeal/oropharyngeal samples within 15-20 minutes. 44 Data on sensitivity and specificity also derive from the manufacturer and a couple of reports from FIND foundation (Table 4) . 45 

Overall clinical sensitivity of RATs has demonstrated to be high; however there is some variability among studies. By contrast, overall specificity is consistently elevated in all of them.

RATs are especially adequate in patients with high viral loads (Ct values ≤25 or >106 genomic virus copies/mL) which frequently present symptoms within the first 5-7 days of the disease. 48 However, symptomatic patients with onset of symptoms beyond 7 days are more likely to show lower viral loads, and thus the likelihood of false negative results with RATs is greater. According to a recent systematic review and meta-analysis with data from 52 studies that evaluated the accuracy of 20 different RATs, sensitivity and specificity are 73.8% (95%CI: 68.6-78.5) and 99.7% (95% CI: 99.3. 99.9), respectively. 49 The WHO established the minimum requirements of sensitivity (≥80%) and specificity (≥97%) for RATs to be used for the diagnosis of SARS-CoV-2 infection when RT-qPCR is unavailable or where prolonged turnaround times preclude clinical utility. 48 Available information on sensitivity and specificity from RATs are relatively scarce and derive from studies with differential designs, participating subjects, and test brands being evaluated. Lateral flow assays are point-of-care formats, and involve simple and easy-to-produce devices. 50 RATs can also provide a result in minutes, in contrast to the few days required with RT-qPCR. 

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Human Coronavirus Infections-Severe Acute Respiratory Syndrome (SARS)

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

COVID-19 and multi-organ response

World Health Organization. COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum

(pheic)-global-research-and-innovation-forum

An analysis of international health regulations emergency committees and public health emergency of international concern designations

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region

Situation of COVID-19 in Spain

Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samples

Rapid SARS-CoV-2 antigen detection assay in comparison with realtime RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus

Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers

Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2

Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing site

Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit

Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial

Clinical assessment of the Roche SARS-CoV-2 rapid antigen test. Diagnosis (Berl)

Performance of a Point-of-Care Test for the Rapid Detection of SARS-CoV-2

The comparative clinical performance of four SARS-CoV-2 rapid antigen tests and their correlation to infectivity in Vitro

Panbio™ COVID-19 Ag rapid test device

Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres

Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test

Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio™ COVID

Antigen Rapid Test (Abbott) compared to RT-qPCR

Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care

Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients

Diagnostic accuracy of the Panbio SARS-CoV-2 antigen rapid test compared with Rt-Pcr testing of nasopharyngeal samples in the pediatric population

Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in communitydwelling subjects with symptoms of potential SARS-CoV-2 infection

Experience with Panbio™ rapid antigens test device for the detection of SARS-CoV-2 in nursing homes

Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age

New CerTest SARS-CoV-2 Card Test, the rapid antigen test for

Coronavirus detection

2019-nCoV Antigen Test (Lateral Flow Method)

Page 19 of 23 J o u r n a l P r e -p r o o f Salvagno et al., 25 Research